登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>Fc gamma RIIA / CD32a >SCJUR-STF069

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service

For research use only.

描述(Description)

The Human CD32a (131H) (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human CD32a (131H) (Gene ID: 2212) exhibiting a higher affinity for IgG2 isotypes compared to CD32a-131R, which can use to evaluate ADCP activity of antibodies in the presence of corresponding target cells. When co-cultured with a target cell and relevant antibody, the antibody simultaneously binds the target cell antigen and CD32a (131H) receptor on the surface of Human CD32a (131H) Jurkat Reporter Cell, resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.

应用说明(Application)

Determination of ADCP activity induced by antibodies.

Fc gamma RIIA / CD32a Assay Principles

生长特性(Growth Properties)

Suspension

筛选标记(Selection Marker)

Puromycin (5 μg/mL) + Hygromycin (20 μg/mL)

培养基(Culture Medium)

RPMI-1640 + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

Fc gamma RIIA / CD32a FACS

Expression analysis of human CD32a on Human CD32a (131H) (Luc) Jurkat Reporter Cell by FACS.
Cell surface staining was performed on Human CD32a (131H) (Luc) Jurkat Reporter Cell or negative control cell using PE-labeled anti-human CD32a antibody.

Protocol

 

Application

Fc gamma RIIA / CD32a APPLICATION

ADCP response to anti-human CD20 antibody (RLU).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 was approximately 0.1054 μg/mL.

Protocol

Fc gamma RIIA / CD32a APPLICATION

ADCP response to anti-human CD20 antibody (FOLD).
Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 277.90.

Protocol

 

Passage Stability

Fc gamma RIIA / CD32a PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD32a (131H) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human CD20 antibody in the presence of Raji cells. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-23.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

ADCP is the mechanism by which antibody-opsonized target cells activate the FcγRs on the surface of macrophages to induce phagocytosis, resulting in internalization and degradation of the target cell through phagosome acidification. ADCP is mediated by FcγIIa (CD32a)-activated macrophages leading to augmented phagocytosis.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Fc gamma RIIA / CD32a靶点信息
英文全称:Low affinity immunoglobulin gamma Fc region receptor II-a
中文全称:低亲和力免疫球蛋白γFc区受体II-a
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床一期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定